Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Safety and Efficacy of a STOPping Strategy Versus Classical Maintenance Dose of JAK Inhibitors in Deep Remission Patients With Ulcerative Colitis
2027. jan. 1.· PHASE4 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
The Impact of Rheumatoid Arthritis Treatments on the Modulation of Extracellular Vesicles and Other Biomarkers Involved in the Development of Lung Cancer
2026. dec. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Revumenib in Patients With Myelofibrosis
2026. dec. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Corrigendum to: Bone marrow mesenchymal stem cells relieve rheumatoid arthritis by blocking JAK/STAT and TLR-4/NF-?B pathways.
2026. dec. 1.· Pakistan journal of pharmaceutical sciences· PUBMED
Vizsgálat
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
2026. nov. 11.· PHASE1_PHASE2 · RECRUITING· CTGOV
Vizsgálat
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
2026. nov. 11.· PHASE1 · RECRUITING· CTGOV
Publikáció
Alteration of macrophage infiltrates in the tumor immune microenvironment following Janus kinase 1 (JAK) inhibition: analysis from a prospective clinical trial in Leiomyosarcoma.
2026. nov. 6.· Oncoimmunology· PUBMED
Publikáció
Impact of nano-chitosan solution on psoriasis-like thin skin lesion induced by imiquimod in Wistar rats: Exploring novel epigenetic role targeting miR-155, JAK2/STAT3/RORC/IL-17A, and MyD88/NF-κB pathways.
2026. nov. 4.· Histology and histopathology· PUBMED
Publikáció
Age-stratified risk of major adverse cardiovascular events with JAK inhibitors in rheumatoid arthritis: A nationwide cohort study.
2026. nov. 2.· Journal of autoimmunity· PUBMED
Publikáció
JAK1/2 inhibition promotes aggressive cutaneous carcinogenesis through COT kinase-mediated alternative MAPK pathway activation.
2026. nov. 2.· The Journal of clinical investigation· PUBMED
Vizsgálat
Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Peri-Transplant Gecacitinib in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
2026. nov. 1.· NA · NOT_YET_RECRUITING· CTGOV
Publikáció
Xiaoshen formula delays progression of diabetic kidney disease and improves glucose and lipid metabolism: Association with the JAK/STAT pathway.
2026. nov. 1.· Pakistan journal of pharmaceutical sciences· PUBMED
Publikáció
Jolkinolide B induces apoptosis and G1 arrest in A549 cells via JAK2/STAT3 inhibition.
2026. nov. 1.· Pakistan journal of pharmaceutical sciences· PUBMED
Publikáció
The Histone Lactylation of KREMEN2 Inhibits Ferroptosis Through the JAK2/STAT3/GPX4 Axis and Promotes the Progression of Mantle Cell Lymphoma.
2026. nov. 1.· Hematological oncology· PUBMED
Publikáció
Progression to Psoriatic Arthritis Among Psoriasis Patients Treated With JAK Inhibitors Compared With IL-17/23 Inhibitors.
2026. nov. 1.· Journal of drugs in dermatology : JDD· PUBMED
Publikáció
Bone marrow mesenchymal stem cells relieve rheumatoid arthritis by blocking JAK/STAT and TLR-4/NF-κB pathways.
2026. nov. 1.· Pakistan journal of pharmaceutical sciences· PUBMED
Publikáció
PELO links PTEN loss to JAK1/STAT1-mediated inflammation and prostate tumor progression by stabilizing JAK1-PIK3R3 interactions.
2026. okt. 31.· Cell death and differentiation· PUBMED
Publikáció
JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series.
2026. okt. 31.· Psoriasis (Auckland, N.Z.)· PUBMED
Publikáció
JAK inhibitor retention and adverse event-related discontinuation in elderly patients with rheumatoid arthritis: a real-world cohort study.
2026. okt. 31.· Clinical rheumatology· PUBMED
Publikáció
GPR183 senses 7α,25-OHC to drive Treg differentiation and tumor immune evasion via AXL-JAK2-STAT5 signaling.
2026. okt. 30.· Science advances· PUBMED
Publikáció
A pectic polysaccharide from Lonicera japonica alleviates DNCB-induced atopic dermatitis-like inflammation associated with gut microbial and metabolic alterations and reduced cutaneous JAK2/STAT3 activation and Th17 responses.
2026. okt. 29.· Journal of ethnopharmacology· PUBMED
Publikáció
Collagen type I alpha 1 chain induces M2 macrophage polarization via integrin α2β1/JAK2/STAT3 pathway to promote gastric cancer progression.
2026. okt. 28.· Tissue & cell· PUBMED
Publikáció
3,4-Dimethoxyacetophenone ameliorates epileptogenesis by suppressing BDNF, c-fos, and JAK-2/ STAT-3 expression in a pentylenetetrazole-induced kindling model of epilepsy.
2026. okt. 28.· Neuropharmacology· PUBMED
Publikáció
CXCL9 Knockdown Inhibits Tumor Progression and Angiogenesis in Clear Cell Renal Cell Carcinoma via JAK-STAT3 Signaling Pathway.
2026. okt. 28.· Oncology research· PUBMED
Publikáció
QRISK3 Assessment Identified Essential Thrombocythemia Patients at High Risk of Thrombotic Events Regardless of Revised IPSET-T Score and JAK2 Mutational Status.
2026. okt. 28.· EJHaem· PUBMED
Publikáció
Non-canonical function of SCIMP restricts JAK1 activity to counteract immune evasion in bladder cancer.
2026. okt. 27.· Journal for immunotherapy of cancer· PUBMED
Publikáció
The JAK3/IL-2Rα axis in Helicobacter pylori-associated macrophage reprogramming: A narrative review of a proposed immunoregulatory framework.
2026. okt. 27.· The Journal of international medical research· PUBMED
Publikáció
Refining atopic dermatitis pathogenesis: Early-life trajectories, noncanonical cytokines, and JAK-STAT signaling.
2026. okt. 27.· The Journal of allergy and clinical immunology· PUBMED